PDGF receptor kinase inhibitors for the treatment of restenosis

Alexander Levitzki

doi:10.1016/j.cardiores.2004.08.008

PDGF receptor kinase inhibitors for the treatment of restenosis

Cardiovasc Res. 2005 Feb 15;65(3):581-6. doi: 10.1016/j.cardiores.2004.08.008.

Author

Alexander Levitzki¹

Affiliation

¹ Unit of Cellular Signaling, Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel. levitzki@vms.huji.ac.il

PMID: 15664384
DOI: 10.1016/j.cardiores.2004.08.008

Abstract

The clogging of arteries by neointima is a hallmark of atherosclerosis and of restenosis following balloon angioplasty. The realization in the 1980s that PDGF and its receptor play a key role in the onset of neointimal formation led us to develop PDGFR kinase inhibitors as antirestenosis agents. In this review, we describe the development of these inhibitors and their implementation as antirestenosis agents by localized delivery to the site of injury.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Angioplasty, Balloon, Coronary
Animals
Coronary Restenosis / drug therapy*
Coronary Restenosis / physiopathology
Enzyme Inhibitors / therapeutic use*
Humans
Receptors, Platelet-Derived Growth Factor / antagonists & inhibitors*
Receptors, Platelet-Derived Growth Factor / physiology
Tyrphostins / therapeutic use

Substances

Enzyme Inhibitors
Tyrphostins
Receptors, Platelet-Derived Growth Factor